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Background: At the end of life goals of care change from disease prevention
to symptomatic control, however, little is known about the patterns of medication
prescribing at this stage.
Objectives: To explore changes in prescribing of symptomatic and preventive
medication in the last year of life in older nursing home residents.
Methods: A retrospective cohort study was conducted using pharmacy medication
supply data of 553 residents from 16 nursing home facilities around Sydney, Australia.
Residents received 24-h nursing care, were aged ≥ 65 years, died between June 2008
and June 2010 and were using at least one medication 1 year before death. Medications
were classified as symptomatic, preventive, or other. A linear mixed model was used to
compare changes in prescribing in the last year of life.
Results: 68.1% of residents were female, mean age was 88.0 (SD: 7.5) years and
residents used a mean of 9.1 (SD: 4.1) medications 1 year before death. The mean
number of symptomatic medications per resident increased from 4.6 medications 1 year
before death to 5.1 medications at death [95% CI 4.4–4.7 to 5.9–5.2, P = 0.000],
while preventive medication decreased from 2.0 to 1.4 medications [95% CI 1.9–2.1
to 1.3–1.5, P = 0.000]. Symptomatic medications were used longer in the last year
of life, compared to preventive medications (336.3 days [95% CI 331.8–340.8] versus
310.9 days [95% CI 305.2–316.7], P = 0.000).
Conclusion: Use of medications for symptom relief increased throughout the last year
of life, while medications for prevention of long-term complications decreased. But
changes were slight and clinical relevance can be questioned.
Keywords: end of life, aged-care, nursing homes, medication use, deprescribing, palliative care, drug utilization,
preventive medicine
INTRODUCTION
At all stages across the life span, the decision to prescribe a medication should be based on weighing
potential benefits and harms of the medication considering the individual’s treatment goals. Goals
range from decreasing mortality and morbidity, prevention of future conditions or complications,
or minimization of symptoms. Toward the end of life, in addition to considerations around
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potential medication related benefits and harms, treatment
choice should also take life expectancy into consideration.
As life expectancy decreases, the goals of care may change
from decreasing mortality and morbidity, to symptom control
(Holmes et al., 2006). Long-term residential aged care or nursing
home residents are among the frailest of all older populations.
They are generally medically complex, using a high number
of medications, and this complexity together with age-related
pharmacokinetic- and dynamic puts them at high risk of
adverse outcomes related to medication (Taxis et al., 2016, 2017;
Australian Institute of Health and Welfare, 2017).
Of all aged care residents, 91% die in the nursing home
after an average stay of 168 weeks for women and 110 weeks
for men, indicating that the majority of residents have limited
life expectancy following nursing home admission (Australian
Institute of Health and Welfare, 2017). Adjusting prescribing
according to a decreasing life expectancy involves deprescribing,
defined as the process of withdrawing inappropriate medications
(Lee et al., 2013; Scott et al., 2015). Hence, in this population a
decrease in preventive and an increase in the use of medications
for symptom control and palliation could be expected (Maddison
et al., 2011).
To date few studies exploring changes in the use of
symptomatic and preventive medications have been conducted
in older nursing home populations at the end of life. A recent
systematic review found that use of preventive medications in
patients with limited life expectancy was common (Poudel et al.,
2017). Only few studies focused on deprescribing and there was
no consensus on how to optimize medication use at the end of
life. Of the 15 studies included, three were performed in a nursing
home setting (Poudel et al., 2017). These studies included only a
small study population (Blass et al., 2008) or had a cross-sectional
study design (Onder et al., 2013; Heppenstall et al., 2016). In
order to consider optimization of medication use at the end of
life we need to understand the current patterns of use as life
expectancy decreases. Therefore, the aim of this study was to
explore changes in prescribing of symptomatic and preventive
medications in the last year of life among older nursing home
residents.
MATERIALS AND METHODS
Study Design and Setting
A retrospective cohort study of 3876 nursing home residents
living in 26 residential aged care (RAC) facilities in New South
Wales, Australia between 1st June 2008 and 10th June 2010.
The RAC facilities varied from low care to high care. High
care facilities provided 24 h nursing care including medication
administration. All residents received medical care from the
general practitioner of their choice and were eligible to receive
annual medication reviews by a pharmacist. Each facility has a
contracted pharmacy for medication supply.
Study Population
Recruitment was done at the facility level. All residents aged
65 years or older who died in one of the 26 RAC facilities between
2nd of June 2008 and 10th of June 2010 were included in the
cohort. To allow medication changes in the year prior to death
to be explored, only those residents who were taking at least one
medication 1 year prior to death were included in the cohort.
Residents who were discharged prior to death were excluded from
the study, as medication use could not be ascertained once they
left the facility.
Data Source
Weekly pharmacy medication supply data, including all
prescription, non-prescription and complementary medications,
were used for the study. The dataset included generic name,
dose, date of commencement, date of cessation and if the use
was regular or ‘as needed.’ The dataset also included limited
demographic data for each resident including age, sex, date of
admission, date and reason for discharge and facility.
Medication Classification
Medications were coded using the World Health Organization
Anatomical Therapeutic Chemical (ATC) code (WHO
Collaborating Centre for Drug Statistics Methodology, 2016a).
Medications were classified into three categories: symptomatic,
preventive, and other. All medications recommended for
symptom control in the Australian national palliative care
guidelines were considered as symptomatic medications
(Palliative Care Expert Group, 2010; Australian Government
Department of Health, 2015). Medications defined in the
literature for primary or secondary prevention of all-cause
mortality were defined as preventive medications (Hilmer
et al., 2012). Preventive medications included antihypertensive
medications (NPS Medicinewise, 2016), antithrombotic agents
(WHO Collaborating Centre for Drug Statistics Methodology,
2016b), osteoporosis medication (NPS Medicinewise, 2017),
and lipid modifying agents (WHO Collaborating Centre for
Drug Statistics Methodology, 2016c). Medications that were not
considered as either preventive or symptomatic were classified
as other. Antibiotics, topical preparations, ophthalmological and
otological medications were excluded due to the episodic nature
of the use of these medications. Vaccines were also excluded
as they were administered by the general practitioner and not
supplied by the pharmacy. A list of included medications can be
found in the Appendix.
Outcomes
Three main outcome measures were determined. First, we
compared the mean number of symptomatic, preventive, and
other medications per resident at 1 year, 6 months, 1 month,
and 1 week (8 days) before death and on the day of death.
Second, we compared the type of symptomatic, preventive, and
other medication used 1 year before death versus on the day of
death. For this analysis we included all medications, grouped by
ATC level 2, which were used by at least 10% of the population
either 365 days before death or on the day of death. Third,
we compared the duration of use of symptomatic, preventive,
and other medications in the last year of life. We included all
medications used 365 days before death, and calculated the days
of treatment during the last year of life.
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FIGURE 1 | Flow chart of resident inclusion.
All medications used 7 or fewer days before death were
considered to be taken on the day of death. This was done for
two reasons. First, medication was supplied per week, therefore
the last medication might have been supplied up to 7 days before
death. Second, we assumed some inaccuracies in recording the
date of death due to a delay in nursing home staff notifying
pharmacy staff.
Statistical Analysis
Medication changes were analyzed with a linear mixed model to
account for clustering of medications within one resident. Our
data did not allow clustering for general practitioners. Therefore
we performed clustering on the level of facility, to account
for possible intra-facility culture of medication prescribing. We
included a random intercept and a random slope at the level of
resident and facility in the analysis. Analyses were adjusted for
age, gender, duration of admission and number of medications at
365 days before death, if the individual P-value in the univariate
analysis was 0.25 or less (Bursac et al., 2008). The number of
medication and days of treatment were reported as estimated
marginal means with their 95% confidence intervals. The second
outcome was analyzed using a McNemar test. We report on
proportions and absolute numbers of residents. All analyses were
conducted in IBM SPSS 24 on a significance level of 0.05.
Ethics Statement
This study was approved by the Sydney South West Area
Health Service Human Research Ethics Committee, the




The cohort comprised of 553 residents out of the 3876 residents
contained in the dataset, see Figure 1.
Residents were between 65 and 105 years of age and lived in
16 different facilities. The average facilities size was 35 (SD: 21)
residents per facility (range: 5–71) (Table 1).
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TABLE 1 | Resident characteristics.
Characteristic Residents
(n = 553)
Age, mean years (SD) 88.0 (7.5)
Gender, % female (number) 68.1 (374)∗
Length of stay in RAC facility, mean weeks (SD) 187.9 (104.4)
Number of medications 365 days before death, mean (SD) 9.1 (4.5)
Number of medications at death, mean (SD) 8.7 (5.1)
∗n = 549, gender was missing for four residents.
Number of Symptomatic, Preventive, and
Other Medications in the Last Year of Life
The total number of medications per resident decreased from
9.1 [95% CI 8.9–9.3] medications 1 year prior to death to 8.5
[95% CI 8.5–8.9] medications at death (P = 0.002). Symptomatic
medication use increased from 4.6 to 5.1 [95% CI 4.4–4.7 to
5.9–5.2, P = 0.000] medications, while preventive and other
medication decreased, respectively 2.0 to 1.4 [95% CI 1.9–2.1
to 1.3–1.5, P = 0.000] and 2.6–2.2 [95% CI 2.4–2.7 to 2.1–2.4,
P = 0.000], toward death (Figure 2).
Type of Symptomatic, Preventive, and
Other Medication Used in the Last Year
of Life
Analgesics were the most frequently used type of medication over
the last year of life. Analgesic use did not change significantly
during the last year of life and was comparable at 1 year before
death and at death (85.0 to 86.1% of patients, P= 0.610). A shift in
the type of analgesics used was seen, shifting from paracetamol to
opioids, respectively 83.4 to 77.9% (P = 0.005) and 18.1 to 44.5%
(P = 0.000). Other significant changes in use of symptomatic
medications toward death were only seen for diuretics (30.2
to 26.0%, P = 0.009) and medications for gastrointestinal
disorders (17.2 to 22.8%, P = 0.000). In contrast, all preventive
medications decreased significantly from 1 year before death until
death. The highest decrease was found in mineral supplements
(including calcium), agents acting on the renin-angiotensin-
aldosterone-system (RAAS) and lipid modifying agents, those
respectively decreased by 9.2% (P = 0.000), 8.9% (P = 0.000),
and 8.1% (P = 0.000) (Table 2). However, at death about one
third of all residents was using at least one antihypertensive
medication (35.8%), one medication for osteoporosis (32.9%) or
an antithrombotic medication (33.1%).
Duration of Use of Symptomatic,
Preventive, and Other Medications in the
Last Year of Life
Symptomatic, preventive, and other medications were used
respectively for 336.3 [95% CI 331.8–340.8], 310.9 [95% CI 305.2–
316.7] and 320.5 [95% CI 315.2–325.8] days in the last year of
life. Preventive and other medications were ceased earlier than
symptomatic medication, respectively 25.4 days earlier [EMM,
95% CI 31.0–19.7, P = 0.000] and 15.8 days earlier [EMM, 95%
CI 20.9–10.7, P = 0.000] (Figure 3).
DISCUSSION
Key Findings
Throughout the last year of life we saw little change in overall
medication use. Medications commonly used for symptom
control slightly increased, while a small decrease in medication
for disease-prevention was seen. However at death, preventive
medication such as antithrombotic agents, antihypertensive
medications, and osteoporosis medications were still prescribed
to one third of all residents.
FIGURE 2 | Number of symptomatic, preventive, and other medication in the last year of life. Estimated marginal means (EMMs), adjusted for number of bed days in
facility∗ age†, and number of medication at 365 days before death‡.
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N02 Analgesics 86.1 1.1 B01 Antithrombotics 33.1 −6.0∗ C01 Cardiac therapy 25.7 −2.7∗
A06 Laxatives 72.9 −0.4 A11 Vitamins 23.9 −5.6∗ N06 Psychoanaleptics 24.2 −6.0∗
N05 Psycholeptics 50.1 −0.4 C09 Agents acting on
the RAAS system







38.3 −3.1 A12 Mineral
supplements
including calcium
17.9 −9.2∗ B03 Anti-anemic
medication
15.9 −2.9







22.8 5.6∗ C10 Lipid modifying
agents
9.9 −8.1∗ H03 Thyroid therapy 11.8 −1.1
N03 Antiepileptic
medication
11.2 2.2 C08 Calcium channel
blocking agents





8.3 −1.8 M05 Drugs for treatment
of bone disease
5.6 −6.5∗
∗McNemar test (df = 552), P < 0.05. 1: percentage of residents taking medication at death – percentage of residents taking medication 365 days before death. RAAS,
renin-angiotensin-aldosterone-system.
FIGURE 3 | Duration of use of symptomatic, preventive and other medication
in the last year of life. ∗We included all medications used 365 days before
death.
Changes in Medication Use at the End of
Life
The characteristics of our cohort of residents are similar to other
studies in this setting, so we believe our sample is representative
for the nursing home population in Australia. The residents’
average duration of stay in the RAC facility was slightly higher
than the national average (Australian Institute of Health and
Welfare, 2017), which might be a consequence of selecting
patients who stayed at least 1 year in the RAC.
We found an increase in symptomatic medication toward
death, which was also seen in a small study looking at the
last 3 months of life (Blass et al., 2008) and another study
focusing at the last week of life (Jansen et al., 2014). The increase
was very subtle, however, and mostly caused by an increase in
gastrointestinal medications. Overall use of analgesics, which
are supposed to be the most prominent medication group in
palliative care (Australian Government Department of Health,
2015), did not change. But the shift from paracetamol to opioid
use indicates some awareness in the changing needs of residents
at the end of life by the GP.
Despite some deprescribing, the use of antithrombotics,
antihypertensives, and osteoporosis medications was very high
at the end of life, similar to other studies (Onder et al., 2013;
Jansen et al., 2014; Heppenstall et al., 2016). An explanation
for this high use could be the lack of consensus on what
medications are considered solely preventive and therefore
inappropriate at the end of life (Todd et al., 2017). We included
antithrombotics, lipid-modifying agents, antihypertensives and
osteoporosis medication, but other studies have also included
iron, antibiotics, acid reducers and medications used in diabetes
(Poudel et al., 2017). An exception to preventive medications,
are lipid-modifying agents. These medications, especially statins,
were unanimously classified as preventive medication and
have been explored the most (Poudel et al., 2017). This
attention to statins might have led to growing awareness of
its inappropriateness at the end of life, resulting in early
deprescribing by GPs. This could explain the lower use of statins
compared to other preventive medication we found in our
study.
Strengths and Limitations
This study is unique in investigating changes in prescribing of
symptomatic and preventive medication in the last year of life in
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a relatively large group of residents. We based the classification
of medications on current guidelines. Some limitations
need be taken into consideration when interpreting our
results. Firstly, we were using medication supply data and
therefore were not able to ascertain actual medication intake.
However, the weekly medication supply ensured that the
dataset remained relatively sensitive to change. Secondly, in
line with other studies using dispensing data, we had no
recorded indication for prescribed medication and therefore
our medication classification was an approximation. We used
the palliative care guidelines for classification of medication
and rely on prescribing following the guidelines for correct
classification. Thirdly, we were not able to cluster our data
at the level of prescriber since each nursing home resident
in Australia has his or her own prescriber. Fourthly, by
investigating prescribing in the last year of life we had to
exclude residents who stayed in the nursing home facility
for a shorter time. Our results may not be generalizable to
residents who died within a few months of nursing home
admission.
CONCLUSION AND IMPLICATIONS FOR
FURTHER RESEARCH
The awareness of deprescribing inappropriate medication at
the end of life is growing throughout the literature. Recent
articles have been published guiding the process of deprescribing
(Scott et al., 2015; Granas et al., 2017; Wouters et al., 2017)
and shared decision making at the end of life (Jansen et al.,
2016). But there still remains a lack of high quality evidence
guiding deprescribing at the end of life (Tjia et al., 2013).
For example aspirin has a number needed to treat of 120
patients over 6 years to prevent one cardiovascular event and
a number needed to harm of 73 for a non-trivial bleedings,
based on a study population with a mean age of 57 years
(Seshasai et al., 2012). The figures are likely to be different in an
older population. Furthermore, contradictory recommendations
and variation in interpretations of guidelines leads to clinical
uncertainty (Alhawassi et al., 2015). An example is the most
recent discussion on blood pressure control in older patients
(Williamson et al., 2016). Exploring the use of preventive
and symptomatic medication use at the end of life is a
first step to improve the quality of medication use for these
patients.
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